Skip to main content
Top
Published in: Rheumatology International 2/2013

01-02-2013 | Original Article

Prevalence and significance of the MEFV gene mutations in childhood Henoch–Schönlein purpura without FMF symptoms

Authors: Cagla Serpil Dogan, Sema Akman, Mustafa Koyun, Turker Bilgen, Elif Comak, Arife Uslu Gokceoglu

Published in: Rheumatology International | Issue 2/2013

Login to get access

Abstract

Familial Mediterranean fever (FMF) has been reported more frequently in patients presenting with Henoch–Schönlein purpura (HSP) than in the general population. But, there is no clear knowledge about MEFV mutations in patients with HSP. We investigated the prevalence of MEFV mutations in children with HSP and without FMF whether these mutations have any effect on the disease course or complications. A total of 76 children with HSP who had no typical symptoms of FMF were screened for the mutations in exon 2 and exon 10 of the MEFV gene. Eleven of 76 patients (14.4 %) were heterozygous (E148Q in 5, M694V in 4, M680I in 1, E148V in 1), 5 (6.6 %) were homozygous (M694V/M694V in 4, V726A/V726A in 1), and 2 (2.6 %) were compound heterozygous (E148Q/M694V mutations in 1 and L110P/E148Q mutations in 1). Altogether, 7 patients carried 2 mutated MEFV alleles (9.2 %), which was higher than that observed in the general Turkish population (1 %). No significant differences in joint, gastrointestinal, renal involvement, or subcutaneous edema, and also acute phase reactants including leukocyte count, erythrocyte sedimentation rate, and serum C-reactive protein concentration were found between the groups. The prevalence of the two allele-MEFV mutations in patients with HSP was found higher than that of the general population. However, it seems that MEFV gene mutations may not have any effect on the clinical presentation of HSP.
Literature
1.
go back to reference Livneh A, Langevitz P, Zemer D et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40:1879–1885PubMedCrossRef Livneh A, Langevitz P, Zemer D et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40:1879–1885PubMedCrossRef
2.
go back to reference Touitou I (2001) The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet 9:473–483PubMedCrossRef Touitou I (2001) The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet 9:473–483PubMedCrossRef
3.
go back to reference Mimouni A, Magal N, Stoffman N et al (2000) Familial Mediterranean fever: effects of genotype and ethnicity on inflammatory attacks and amyloidosis. Pediatrics 105(5):E70PubMedCrossRef Mimouni A, Magal N, Stoffman N et al (2000) Familial Mediterranean fever: effects of genotype and ethnicity on inflammatory attacks and amyloidosis. Pediatrics 105(5):E70PubMedCrossRef
4.
go back to reference Ben-Chetrit E, Backenroth R (2001) Amyloidosis induced, end stage renal disease in patients with familial Mediterranean fever is highly associated with point mutations in the MEFV gene. Ann Rheum Dis 60:146–149PubMedCrossRef Ben-Chetrit E, Backenroth R (2001) Amyloidosis induced, end stage renal disease in patients with familial Mediterranean fever is highly associated with point mutations in the MEFV gene. Ann Rheum Dis 60:146–149PubMedCrossRef
5.
go back to reference Kutlay S, Yilmaz E, Koytak ES, Tulunay OO, Keven K, Ozcan M, Ertürk S (2001) Case of familial Mediterranean fever with amyloidosis as the first manifestation. Am J Kidney Dis 38(6):E34PubMedCrossRef Kutlay S, Yilmaz E, Koytak ES, Tulunay OO, Keven K, Ozcan M, Ertürk S (2001) Case of familial Mediterranean fever with amyloidosis as the first manifestation. Am J Kidney Dis 38(6):E34PubMedCrossRef
6.
go back to reference Ozdogan H, Arisoy N, Kasapçapur O et al (1997) Vasculitis in familial Mediterranean fever. J Rheumatol 24:323–327PubMed Ozdogan H, Arisoy N, Kasapçapur O et al (1997) Vasculitis in familial Mediterranean fever. J Rheumatol 24:323–327PubMed
7.
go back to reference Tekin M, Yalçinkaya F, Tümer N, Akar N, Misirlioğlu M, Cakar N (2000) Clinical, laboratory and molecular characteristics of children with Familial Mediterranean Fever-associated vasculitis. Acta Paediatr 89:177–182PubMedCrossRef Tekin M, Yalçinkaya F, Tümer N, Akar N, Misirlioğlu M, Cakar N (2000) Clinical, laboratory and molecular characteristics of children with Familial Mediterranean Fever-associated vasculitis. Acta Paediatr 89:177–182PubMedCrossRef
8.
go back to reference Touitou I, Magne X, Molinari N et al (2000) MEFV mutations in Behçet’s disease. Hum Mutat 16:271–272PubMedCrossRef Touitou I, Magne X, Molinari N et al (2000) MEFV mutations in Behçet’s disease. Hum Mutat 16:271–272PubMedCrossRef
9.
go back to reference Saulsbury FT (2007) Clinical update: Henoch-Schönlein purpura. Lancet 24:976–978CrossRef Saulsbury FT (2007) Clinical update: Henoch-Schönlein purpura. Lancet 24:976–978CrossRef
10.
go back to reference Ozen S, Pistorio A, Iusan SM et al (2010) EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis 69:798–806PubMedCrossRef Ozen S, Pistorio A, Iusan SM et al (2010) EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis 69:798–806PubMedCrossRef
11.
go back to reference Gershoni-Baruch R, Broza Y, Brik R (2003) Prevalence and significance of mutations in the familial Mediterranean fever gene in Henoch-Schönlein purpura. J Pediatr 143:658–661PubMedCrossRef Gershoni-Baruch R, Broza Y, Brik R (2003) Prevalence and significance of mutations in the familial Mediterranean fever gene in Henoch-Schönlein purpura. J Pediatr 143:658–661PubMedCrossRef
12.
go back to reference Ozçakar ZB, Yalçinkaya F, Cakar N et al (2008) MEFV mutations modify the clinical presentation of Henoch-Schönlein purpura. J Rheumatol 35:2427–2429PubMedCrossRef Ozçakar ZB, Yalçinkaya F, Cakar N et al (2008) MEFV mutations modify the clinical presentation of Henoch-Schönlein purpura. J Rheumatol 35:2427–2429PubMedCrossRef
13.
go back to reference Bayram C, Demircin G, Erdoğan O, Bülbül M, Catlık A, Akyüz SG (2011) Prevalence of MEFV gene mutations and their clinical correlations in Turkish children with Henoch-Schönlein purpura. Acta Paediatr 100:745–749PubMedCrossRef Bayram C, Demircin G, Erdoğan O, Bülbül M, Catlık A, Akyüz SG (2011) Prevalence of MEFV gene mutations and their clinical correlations in Turkish children with Henoch-Schönlein purpura. Acta Paediatr 100:745–749PubMedCrossRef
14.
go back to reference Yilmaz E, Ozen S, Balci B et al (2001) Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet 9:553–555PubMedCrossRef Yilmaz E, Ozen S, Balci B et al (2001) Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet 9:553–555PubMedCrossRef
15.
go back to reference Mir S, Yavascan O, Mutlubas F, Yeniay B, Sonmez F (2007) Clinical outcome in children with Henoch-Schönlein nephritis. Pediatr Nephrol 22:64–70PubMedCrossRef Mir S, Yavascan O, Mutlubas F, Yeniay B, Sonmez F (2007) Clinical outcome in children with Henoch-Schönlein nephritis. Pediatr Nephrol 22:64–70PubMedCrossRef
16.
go back to reference Xia Y, Mao J, Chen Y et al (2011) Clinical outcomes in children with Henoch-Schönlein purpura nephritis grade IIIa or IIIb. Pediatr Nephrol 26:1083–1088PubMedCrossRef Xia Y, Mao J, Chen Y et al (2011) Clinical outcomes in children with Henoch-Schönlein purpura nephritis grade IIIa or IIIb. Pediatr Nephrol 26:1083–1088PubMedCrossRef
17.
go back to reference Niaudet P, Habib R (1998) Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis. Pediatr Nephrol 12:238–243PubMedCrossRef Niaudet P, Habib R (1998) Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis. Pediatr Nephrol 12:238–243PubMedCrossRef
18.
go back to reference Narchi H (2005) Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 90:916–920PubMedCrossRef Narchi H (2005) Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 90:916–920PubMedCrossRef
Metadata
Title
Prevalence and significance of the MEFV gene mutations in childhood Henoch–Schönlein purpura without FMF symptoms
Authors
Cagla Serpil Dogan
Sema Akman
Mustafa Koyun
Turker Bilgen
Elif Comak
Arife Uslu Gokceoglu
Publication date
01-02-2013
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 2/2013
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-012-2400-x

Other articles of this Issue 2/2013

Rheumatology International 2/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.